drug · antibody
relatlimab
Phase 2updated 3mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 6Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for melanoma and 13 investigational indications.
indications
indications
NSCLCColorectal CancerDLBCL
targets
Lymphocyte activation gene 3 protein
all catalysts(0)
nothing on the calendar yet
Trials studying relatlimab
- phase2Pan Tumor Rollover Study
- phase2Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
- phase2Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- phase3VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- phase2Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
- phase2A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- phase1Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
- phase3A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
News(1)
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 3mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that